RxDoctor Payments Data

Tariq Kutob, MD

Internal Medicine · Pinellas Park, FLNPI 1497844120

Payments from drug & device makers

$4,393in general payments, 2019–2025

Across 76 payments — averaging $57.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$629
  • AbbVie$497
  • Bayer$382
  • Novo Nordisk$292
  • Lilly USA, LLC$195
  • plus $730 from 10 others

What the payments were for

  • Food & beverage$4,373100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,393 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$22,318
Medicare patients
57
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol56$47,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,787
TrulicityDulaglutide15$16,197
RybelsusSemaglutide12$13,554
Atorvastatin Calcium204$2,133
Albuterol Sulfate HfaAlbuterol Sulfate43$1,449
Rosuvastatin Calcium73$1,229
Levothyroxine Sodium95$1,068
Omeprazole38$870
Lisinopril110$777
Losartan Potassium45$734
Amlodipine Besylate88$627
Cyclobenzaprine Hcl17$617
Duloxetine Hcl19$602
Gabapentin52$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,669$47,73956 claims
GSKTrelegy Ellipta$629$17,78714 claims
Lilly USA, LLCTrulicity$195$16,19715 claims
Novo NordiskRybelsus$292$13,55412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pinellas Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →